Skip to main content
NewslettersWatchlist

Abcellera Biologics Inc(ABCL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.71
Day High2.83
Open:2.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
AbCellera to Present at Upcoming Investor Conferences in December and January
Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Motley Fool
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Business Wire
AbCellera Reports Q3 2024 Business Results
Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
Barchart
Should You Follow Insider Buying on This Biotech Penny Stock?
Motley Fool
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
Barchart
1 Billionaire-Backed Penny Stock With 421% Upside
Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Motley Fool
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Motley Fool
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Barchart
3 AI-Driven Drug Stocks to Buy Before They Breakout
The Globe and Mail
Short sales on the TSX: What bearish investors are betting against
Motley Fool
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
Motley Fool
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Motley Fool
3 Growth Stocks That Could Go Parabolic in 2024
The Globe and Mail
AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer
SYNDTGAM
Cutting-edge antibody therapy firm AbCellera to lay off 10% of work force
Motley Fool
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Profile

AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.